Psychedelics

Company Gets Trademark for the Word ‘Psilocybin’

Kyle Jaeger, writing for Marijuana Moment:

As psychedelics reform efforts pick up across the U.S., there’s an increasing weariness among advocates about the potential corporatization that may follow.

That’s why many found it alarming when a California-based company announced on Thursday that it had successfully trademarked the word “psilocybin,” the main psychoactive constituent of so-called magic mushrooms.

Psilocybin™ is a brand of chocolates that do not contain the psychedelic itself but are meant to “begin educating, enlightening and supporting the community in upgrading their inner vibrations in order to get everything they want of their time here on earth,” according to a mission statement.

It’s been more than ten years since I took a mass media law class in college to earn my journalism undergraduate degree, but even armed with the info I learned in that course I have to admit that I was surprised to see that this kind of a thing is even possible, much less something that actually happened already.

After looking into it I discovered that two other companies have submitted requests to trademark drug terms. Weed Cellars trademarked “weed” last year and MedMen attempted to trademark the word “cannabis” a couple years ago, although that would’ve only applied to printing the word on clothing.

The fact that these brands are getting exclusive rights to use widely-accepted names of drugs is beyond dumbfounding—it’s just plain dumb.


Study Finds Nitrous Oxide Can Ease Depression Symptoms

Daily Mail:

Laughing gas can ease symptoms of depression in just two hours, new research suggests.

A pilot study involving 20 patients who’d previously not responded to up to 12 different antidepressants found they were significantly more likely to improve with ‘laughing gas’ treatment than those given a placebo gas. The benefits lasted several days.

Now, in a new four-week study, 200 patients with depression will be treated with a mix of nitrous oxide (commonly known as laughing gas) and oxygen for an hour.

This is the first I’ve heard of using nitrous oxide to treat depression, but it makes sense that it could work. After all, ketamine (which is also classified as a psychedelic dissociative) has proved effective for treating depression too. These drugs work in the brain a bit differently than traditional antidepressants, acting on glutamate instead of serotonin or dopamine.

Psychedelic drugs like nitrous and ketamine might eventually begin to cannibalize the market for today’s antidepressants, but you can bet your bottom dollar that players in the pharmaceutical industry will try to maximize their market shares of the future pharmaceutical psychedelic medicine market.


Compass Pathways Granted Patent for New Psilocybin Formulation

The story about Compass Pathways’ new patent first broke in a press release on Monday:

COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use of COMPASS's synthesised investigational psilocybin formulation, COMP360, in a psilocybin therapy protocol for patients with treatment-resistant depression. Psilocybin is an active ingredient in so-called 'magic mushrooms'.

Last month, COMPASS reported that COMP360 was well tolerated when administered to healthy adult volunteers with support from specially trained therapists in a randomised placebo-controlled trial. COMPASS is currently running a phase IIb clinical trial of COMP360 in treatment-resistant depression.This trial is recruiting 216 patients from across Europe and North America who suffer with depression that hasn't responded to established medications, and will be the largest clinical trial of a psilocybin formulation to date. In 2018, COMPASS received FDA "Breakthrough Therapy" designation for its programme of psilocybin therapy for treatment-resistant depression.

Although this wasn’t a clear description of what the patent actually covers, fortunately the patent’s abstract clarified things a little bit:

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

So it turns out that Compass received a patent for its new method of creating large quantities of crystalline psilocybin, which you might recall Psychedelic Science Review covered a couple weeks ago, when Barb Bauer explored how this new crystal form could catalyze the development of new pharmaceutical psychedelics.

Regardless of whether you think pharmaceutical psychedelics should exist or not, make no mistake—they’re coming. Fast.


A Single Dose of Psilocybin Mushrooms Can Reduce Anxiety for Nearly Five Years

Chris Moore, writing for MERRY JANE:

In the original 2016 study, researchers gave a single dose of psilocybin to 29 people suffering from life-threatening forms of cancer. Each of these patients was previously diagnosed with anxiety and/or depression as a direct result of their illness. Six months after taking this single dose, between 60 and 80 percent of patients reported a significant reduction in symptoms of depression and anxiety.

Years later, the original research team followed up with patients from the original study to see if the positivity generated from the psilocybin experience was still in effect. Out of the surviving 16 patients, 15 agreed to take additional psychological assessments between 3.2 and 4.5 years after the initial study.

“Reductions in anxiety, depression, hopelessness, demoralization, and death-anxiety were sustained at the first and second follow-ups,” the authors wrote in the follow-up study, published in the Journal of Pharmacology. At the second follow-up, 4.5 years after the original study, 60 to 80 percent of patients still showed signs of decreased anxiety and depression. “Participants overwhelmingly (71-100%) attributed positive life changes to the psilocybin-assisted therapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.”

What a remarkable result. To think that a person who suffers from anxiety or depression could eat a few magic mushrooms (or in this case, take a psilocybin pill) alongside a trained psychotherapist and experience significant mental health improvements for the next 4.5 years is simply amazing. The pharmaceutical industry is almost certainly taking note of this news and will do its damnedest to find a way to capitalize on psychedelics like psilocybin.

However, it’s important to keep in mind that although this follow-up study reported excellent results, it focused on a very small group of subjects: only 15 people agreed to participate. But these data do confirm something that myself and others around the world have found to be true anecdotally—psychedelics, taken with the proper set and setting in mind and with a focus on preparation and integration, can be incredibly healing medicines.


South Carolina Is Launching A Psychedelic Research Center

FITSNews:

The Medical University of South Carolina (MUSC) is preparing to launch a new psychedelic research center with a sizable endowment, sources familiar with the situation tell this news outlet. The project will reportedly be a collaboration between the school and the Multidisciplinary Association for Psychedelic Studies (MAPS), a group which exists to develop “medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.”

It’s nice to see a new psychedelic research center opening up, and even nicer that it’s just one state away from me. It might take a little while for it to come online though:

According to our sources, the new project will come online within the next eighteen months and will be spearheaded by Dr. Michael Mithoefer, who works in MUSC’s department of psychiatry and behavioral sciences.

Mithoefer has previously researched the use of MDMA (a.k.a. “ecstasy” or “molly”) in concert with psychotherapy to treat individuals suffering from chronic post-traumatic stress disorder (PTSD).

If you’re skeptical of the quality of research that will come out of a center that is opening up in the Bible Belt, that’s completely understandable. But Mithoefer’s involvement is a good sign.